Updated Insights on Vaccines for Respiratory Illnesses
Is tai chi effective against persistent insomnia? Let's examine the World Health Organization's advice on GLP-1 treatments for weight management. Are oral corticosteroids risky during gestation? And what new proof exists for vaccines targeting COVID-19, RSV, and influenza?
These are the subjects we'll explore today, focusing on major health developments. Seasonal gatherings, like Thanksgiving in the U.S., often bring upper respiratory infections. Let's review the latest from the New England Journal of Medicine on vaccinations for various respiratory ailments.
This is crucial due to ongoing debates about vaccine reliability and shifts in U.S. immunization policies. The analysis covers 2025-2026 recommendations, conducting a thorough review of approved vaccines against COVID-19, RSV, and flu since the last ACIP update. They assessed each vaccine's performance, including protection against severe illness and safety profiles, drawing from over 17,000 sources, with 500 studies meeting criteria.
For mRNA COVID-19 vaccines, pooled effectiveness in preventing hospitalizations reached about 50% in general and immunocompromised adults. Against the KP.2 variant, it rose to 68%. RSV vaccination, administered to mothers for newborn defense or to those 60 and older, showed 68% effectiveness in averting hospital stays. Influenza vaccines offered 48% pooled effectiveness in adults aged 18-64 and 67% in kids for hospitalization prevention.
Rare adverse events included myocarditis, affecting 1 to 3 per 100,000 doses, mainly in men, and Guillain-Barré syndrome with 18.2 extra cases per million doses in seniors. In summary, recent data confirms the safety and efficacy of these immunizations for the upcoming season.
Regarding RSV, fresh data indicates protection in older adults fades after the first year. Boosters may be necessary for sustained effectiveness in this group.
Similarly, evolving viruses require updated formulations for COVID and flu. RSV proves effective initially but diminishes over time, weaker beyond the first year.
You didn't mention flu vaccine hospitalization reduction in those over 65. Indeed, it stands at 42% effectiveness, which is quite robust.
A colleague noted that respiratory virus vaccines aim to lessen severity, not eradicate infection, as achieving full immunity is challenging.
Agreed, they cut down on serious outcomes leading to hospital care and lower death rates from these infections.
The clear public health directive is to vaccinate for personal and community benefit.
The advantages far exceed the tiny risks of complications.
Tai Chi Versus Cognitive Behavioral Therapy for Persistent Insomnia
Now, shifting to the British Medical Journal on chronic sleeplessness in middle-aged and elderly individuals, a widespread global problem.
The research compared cognitive behavioral therapy for insomnia (CBT-I) with tai chi among Chinese participants aged 50+ diagnosed with long-term insomnia, to determine which better alleviated symptoms.
At a single Hong Kong site, 200 took part. Key measure was Insomnia Severity Index change at 3 and 15 months post-intervention, after training in both methods.
By month 3, tai chi reduced scores by 6.67, CBT-I by 11.19, showing tai chi less effective initially.
At 15 months, both groups had similar outcomes, indicating sustained tai chi benefits not seen early on.
Factors like ease of access matter; CBT-I specialists are scarce, while tai chi classes abound. More participants stuck with tai chi after the study ended compared to CBT-I.
Tai chi proves affordable and readily available, unlike CBT requiring health professionals. It's suitable for older adults, with over 4 million U.S. practitioners.
Remarkably, CBT is the primary insomnia treatment, impacting half of those 65+, often recurring in three-quarters of cases.
Post-teaching, retention of CBT skills drops, with only 15% continuing after a year, versus double for tai chi.
